Bressanone

This research investigates the relationship between vitamin D levels, bone metabolism, and obesity in children aged 3 to 15 years who have experienced low-energy trauma. The study compares children with fractures confirmed by X-rays to those with similar injuries but no fractures. It aims to understand how factors like vitamin D deficiency, bone metabolic markers, and body weight contribute to fracture risk in pediatric populations. Children are divided into two groups based on fracture status and undergo baseline assessments including height, weight, and dietary calcium intake via questionnaire. Blood samples are collected within 7 days of injury without fasting and kept on ice to accurately measure bone markers such as 25-hydroxyvitamin D, parathyroid hormone, alkaline phosphatase, calcium, and phosphate. The primary focus is on how serum alkaline phosphatase correlates with fractures, while secondary measures include calcium levels, vitamin D status, a combined bone risk score, and body mass index percentile. Participants provide blood and dietary information shortly after their injury, allowing researchers to analyze bone health and fracture risk using statistical methods like logistic regression. The study monitors these markers within a week of trauma to identify predictors of fractures and develop a comprehensive risk profile. This information may help guide future prevention and clinical care strategies for children's bone health.

Researchers are conducting a multicenter prospective observational study focused on patients with newly diagnosed oligometastatic prostate cancer, defined by specific criteria that exclude high metastatic volume disease. The study aims to create a registry of patients from major urological centers in the Triveneto region to assess the cancer outcomes and quality of life impacts of local treatments on the primary tumor alongside systemic hormonal therapies. Participants receive local treatment for the primary prostate tumor, which may include surgery or radiotherapy, combined with systemic hormone therapy. The systemic treatment options include androgen deprivation therapy alone or combined with Docetaxel or androgen receptor signaling inhibitors. Patients must have low-volume metastatic disease according to CHAARTED criteria, without prior local treatment of the primary tumor, and may have been on systemic therapy for less than six months before enrollment. During the study, researchers will monitor overall survival from the start of the chosen treatment up to three years. Participants will be evaluated for cancer progression, quality of life, and treatment effects while receiving local and systemic therapies. The study involves informed consent, regular follow-ups, and assessment of performance status to ensure safety and effectiveness of the combined treatment approach over time.